ABT
Abbott Laboratories · Healthcare · Medical - Devices
Semua angka kepemilikan: hanya manajer 13F yang dipantau, posisi saham biasa, periode pelaporan Q2 2024
| Kuartal | Pemegang | Δ | Saham | Nilai yang dilaporkan | Baru | Keluar |
|---|---|---|---|---|---|---|
| Q2 2026 | 180 | 0 | 1.09B | $98.86B | +5 | −6 |
| Q1 2026 | 184 | +3 | 1.11B | $114.25B | +7 | −5 |
| Q4 2025 | 180 | +2 | 1.17B | $146.24B | +3 | n/a |
| Q3 2025 | 24 | 0 | 623.34M | $83.47B | +1 | −2 |
| Q2 2025 | 22 | 0 | 527.92M | $71.78B | +1 | −1 |
| Q1 2025 | 19 | 0 | 196.20M | $26.01B | +1 | −1 |
| Q4 2024 | 19 | -1 | 182.48M | $20.63B | n/a | −1 |
| Q3 2024 | 19 | 0 | 108.33M | $12.33B | +1 | −1 |
| Q2 2024 | 19 | n/a | 110.87M | $11.51B | n/a | n/a |
| # | Manajer | Saham | Δ saham | Nilai | Bobotnya | Dipegang | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (pasif) | 34.41M | n/a | $3.57B | 0.3% | n/c | 1 | SEC ↗ ×2 |
| 2 | Wellington Management ✦ | 25.53M | n/a | $2.65B | 0.5% | n/c | 1 | SEC ↗ ×8 |
| 3 | Norges Bank ✦ (pasif) | 20.36M | n/a | $2.12B | 0.3% | n/c | 1 | SEC ↗ |
| 4 | Fisher Asset Management ✦ | 10.52M | n/a | $1.09B | 0.5% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 4.06M | n/a | $422.13M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 2.38M | n/a | $247.25M | 0.6% | n/c | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 2.33M | n/a | $241.93M | 0.2% | n/c | 1 | SEC ↗ |
| 8 | Arrowstreet Capital ✦ | 2.30M | n/a | $239.03M | 0.2% | n/c | 1 | SEC ↗ |
| 9 | Bridgewater Associates ✦ | 1.67M | n/a | $173.37M | 0.9% | n/c | 1 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 1.65M | n/a | $171.94M | 0.3% | n/c | 1 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 1.56M | n/a | $162.35M | 0.3% | n/c | 1 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 1.02M | n/a | $105.87M | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 13 | Citadel Advisors ✦ | 983.92K | n/a | $102.24M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 14 | PRIMECAP Management ✦ | 930.93K | n/a | $96.73M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 871.20K | n/a | $90.42M | 0.1% | n/c | 1 | SEC ↗ ×3 |
| 16 | Marshall Wace ✦ | 216.34K | n/a | $22.48M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 34.73K | n/a | $3.61M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | GAMCO Investors ✦ | 22.96K | n/a | $2.39M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Dodge & Cox ✦ | 17.86K | n/a | $1.86M | 0.0% | n/c | 1 | SEC ↗ |
"Their weight" = porsi posisi dari nilai ekuitas 13F yang dilaporkan manajer tersebut: ukuran keyakinan. ✦ = manajer yang dikurasi.
Pembeli baru
| Tidak ada pembeli terlacak baru kuartal ini. |
Telah keluar
| Tidak ada keluar yang terlacak kuartal ini. |
Konteks pasar penuh: di SEMUA filer 13F (data terstruktur SEC, Q1 2026): 3,058 pemegang, 1.35B saham, $133.47B dilaporkan. Ini adalah periode berbeda yang lebih lama dibandingkan angka semesta yang dilacak di atas, dan keduanya tidak pernah dicampur.
Apa lagi yang paling sering dimiliki oleh pemegang sekuritas ini yang dilacak: jumlah kepemilikan bersama, bukan hubungan fundamental.
Pembelian di pasar terbuka (P)
Tidak ada pembelian insider di pasar terbuka dalam jendela cakupan kami.
Penjualan di pasar terbuka (S)
Officer · 27 lbr · $2,958
Officer, Director · 180.30K lbr · $20.95M
Officer, Director · 218.53K lbr · $25.26M
Officer · 5.85K lbr · $642,506
Penghargaan, eksekusi, dan pemotongan pajak tidak pernah dihitung sebagai pembelian atau penjualan di sini. Metodologi